Rinorrea secundaria a espironolactona

Servicio deUrgencias. Hospital Universitario deCanarias. Santa Cruz de Tenerife. Espana.1. Florez J, Armijo JA, Mediavilla A. Far-macologia humana. 2.a ed. Barcelona:Masson, 1992.2. Barclay TS, Tsourounis C, McCart GM.Glucosamine. Ann Pharmacother 1998;32:574-9.3. Towheed TE, Anastassiades TP. Glucosa-mine and chondroitin for treating symp-toms of osteoarthritis. Evidence is widelytouted but incomplete. JAMA2000;283:1483-4.4. McAlindon TE, La Balley MP, Gulin JP,Felson DT. Glucosamine and chondroi-tin for treatment of osteoarthritis. A sys-tematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.5. Ficha tecnica de Xicil®. LaboratoriosRottapharm, S.A. Valencia6. Ficha tecnica de Hespercorbin®.Labora-torios Fides-Ecopharma, S.A., 1996.7. Base de datos Micromedex Drugdex,2001 Micromedex Health care SeriesVol. 109 expres 9/2001.8. Communique: glucosamine sulfate: hy-perglycemia. Can Adverse Drug ReactNewsl 2000;10:4.9. Towheed TE, Anastassiades TP, Shea B,Houpt J, Welch V, Hochberg MC. Glu-cosamine therapy for treating osteoarth-ritis (Cochrane Review). En: The Coch-rane Library, Issue 2, 2002. Oxford:Update Software.10.Communique: Warfarin and glucosami-ne: interaction. Can Adverse Drug ReactNewsl 2001;11:8.